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Abstract Several lines of evidence exist that axon guidance
genes are involved in cancer pathogenesis. Axon guidance
genes ROBO1 and ROBO2 are candidate tumor suppressor
genes (TSG). The aim of our study was to address whether
ROBO1 and ROBO2 expressions are altered in prostate can-
cers (PCA). In this study, we analyzed ROBO1 and ROBO2
expressions in 107 PCAs. In the immunohistochemistry, loss
of ROBO2 expression was identified in 66 % of PCAs and
was significantly higher than that in normal cells (p< 0.001).
By contrast, there was no significant difference of ROBO1
expression between normal and PCAs. Our results indicate
that axon guidance protein ROBO2 is frequently lost in PCA
and that ROBO2 might be involved in PCA pathogenesis as a
candidate TSG.
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Introduction
Mounting evidence indicates that signaling pathways implicat-
ed in development are altered in tumorigenesis as well [1].
SLIT proteins bind ROBO proteins and are involved in axon
guidance during development [2]. In addition, SLIT/ROBO
interactions play important roles in many processes, including
apoptosis, motility, angiogenesis and invasion of cancer cells
[2]. For example, decrease of SLIT/ROBO interaction leads to
loss of E-cadherin expression [3, 4]. ROBO1-deficient mice
suffer from cancer development [5]. Axon guidance genes
ROBO1 and ROBO2 are frequently lost in many cancers
(head/neck, breast, lung, kidney and uterine cancers), and con-
sidered tumor suppressor genes (TSG) in them [6–9]. In pros-
tate cancers (PCA), mRNA expression of axon guidance genes
were frequently altered [10]. ROBO1 mRNA expression was
down-regulated compared with normal prostate tissues, while
ROBO2 mRNA expression was not altered [10]. However, it
remains unclear whether ROBO1 and ROBO2 expression is
altered in PCA at protein level. In this study, we analyzed
expression of ROBO1 and ROBO2 proteins in PCA tissues.
Materials and Methods
For this, tissue microarray (TMA) blocks containing normal
and PCA tissues of 107 patients were used. The PCA were
surgically resected 107 adenocarcinomas, and consisted of
one Gleason score 5, 10 score 6, 47 score 7, 10 score 8 and
39 score 9 cancers. In addition, prostate intraepithelial neo-
plasia (PIN) were included in the TMA of 20 patients’ spec-
imens. Age of the patients ranged 43–77 years with an average
of 67.6 years. Sizes of the cancers ranged 1.1–5.0 cm in
diameter with an average of 2.5 cm. Approval was obtained
from the institutional review board for this study.
Using TMA tissue section series, immunohistochemistry for
ROBO1 and ROBO2 were performed using ImmPRESS
System (Vector Laboratories, Burlingame, CA, USA).
Antibodies for human for ROBO1 (GeneTex, Irvine, CA,
USA; dilution 1/400) and ROBO2 (Santa Cruz Biotechnology,
Santa Cruz, CA, USA; dilution 1/50) were used as primary
antibodies. After deparaffinization, heat-induced epitope re-
trieval was conducted by immersing the slides in Coplin jars
filled with 10 mmol/L citrate buffer (pH 6.0) and boiling the
buffer for 30 min in a pressure cooker (Nordic Ware,
Minneapolis, MN, USA) inside a microwave oven at 700 W;
the jars were then cooled for 20 min. Reaction products were
developed with diaminobenzidine and counterstained with
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hematoxylin. Other procedures were performed as described
previously [11–13]. Under light microscope, tumors were
interpreted as positive when 20–100 % of the cells showed
moderate to intense cytoplasm and/or nuclear staining, and as
negative when 0–19 % of the cells showed staining by immu-
nohistochemistry. The results were reviewed independently by
two pathologists. As negative controls, a slide was treated by
replacement of primary antibody with the blocking reagent.
The immunostaining was judged to be specific by absence of
consistent immunostaining of cells by replacement of primary
antibody with the blocking reagent. Also, reduction of signal
intensity was observed as dilution of the antibody was in-
creased. For the statistical analysis of the immunohistochemi-
cal data, we used χ2 and Fisher’s exact tests.
Results and Discussion
In the PCA, immunopositivity for ROBO1 was observed in
102 (95 %) of the 107 PCAs (Fig. 1a). Normal prostate
glandular cells displayed positive ROBO1 immunostaining
in all cases (Fig. 1a). There was no significant difference of
ROBO1 expression between normal and PCA (Fisher’s exact
test, p> 0.05). PIN lesions showed ROBO1 expression in all
cases. By contrast, ROBO2 expression was positive only in 36
of the PCA (34 %), while normal prostate glandular cells
displayed positive ROBO1 immunostaining in all cases
(Fig. 1b and c). ROBO2 expression in PCAwas significantly
higher than that in normal cells (Fisher’s exact test, p< 0.001).
PIN showed ROBO2 expression in 40 % of the cases
(Fig. 1d). ROBO2 expression was significantly different be-
tween normal and PIN (Fisher’s exact test, p< 0.001), but not
different between PCA and PIN (Fisher’s exact test, p> 0.05).
Next, we analyzed relationship between ROBO2 expression
and pathologic parameters (age, tumor size, vascular invasion,
Gleason score and stage). However, we were not able to find
any significant association (χ2 test, p >0.05).
Because a previous study [2] showed loss of ROBO1
protein in many cancer types and an earlier study [10] showed
loss of ROBO1 mRNA expressed compared with normal
prostate, we expected to find loss of ROBO1 in PCA.
However, we found no difference of ROBO1 protein expres-
sion between normal and PCA tissues. Unexpectedly, howev-
er, we found that ROBO2 expression is lost in 2/3 of the PCA.
Our study also identified that PIN were negative for ROBO2
expression, suggesting that decrease of ROBO2 expression
might occur at an early stage of PCA development. In addition
to expressional alterations, somatic mutations of both ROBO1
and ROBO2 have been reported in pancreatic cancers and
fluke-associated cholangiocarcinomas [14, 15]. Recent
whole-exome sequencing analyses identified neither ROBO1
or ROBO2 mutation in PCA [16, 17], suggesting that somatic
mutation of ROBO1 and ROBO2 genes may be rare in PCA.
In conclusion, our data suggest that loss of axon guidance
molecule ROBO2, rather than ROBO1, might be involved in
PCA tumorigenesis as a TSG.
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Fig. 1 Visualization of ROBO1
and ROBO2 expressions in
prostate cancer tissues by
immunohistochemistry. a Both
normal prostate epithelial cells
(N) and cancer cells (T) are
positive for ROBO1
immunostaining. b A prostate
cancer shows negative ROBO2
immunostaining in the cancer
cells (T), whereas normal
epithelial cells (N) are positive for
ROBO2 immunostaining. c
Another prostate cancer shows
positive ROBO2 immunostaining
in the cancer cells. d A PIN lesion
shows negative ROBO2
immunostaining in the cells
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